Relying on Renagel
Executive Summary
In the second of a two-part series focused on Genzyme's European operations, In Vivo Europe Rx looks at how Genzyme is addressing the challenges facing Renagel's uptake in Europe-cost-conscious reimbursement authorities, cheaper competitors and conservative physicians-in order to secure its most important mid-term growth source.
You may also be interested in...
Actelion: Pharmacovigilant
Actelion didn't exactly hit the jackpot when OGS signed the Swiss company up to market its embattled Zavesca in Europe. But the move will cost Actelion little, and highlights that company's emerging status as a product-focused and independent biotech company, and a valuable marketing partner for niche drugs.
On The Cusp: UK Biotech Verona Pharma Awaits Potential Blockbuster
Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.
Re-Thinking Rare Disease
Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.